Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease - PubMed (original) (raw)
Review
Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease
Todd E Golde et al. Curr Alzheimer Res. 2006 Dec.
Abstract
Advances in the understanding of Alzheimer's disease (AD) pathogenesis provide strong support for a modified version of the amyloid cascade hypothesis, which is now often referred to as the amyloid beta protein (Abeta) cascade hypothesis. The basic tenant of this modified hypothesis is that Abeta aggregates trigger a complex pathological cascade leading to neurodegeneration. Thus, as opposed to the original amyloid hypothesis, whose basic tenant was that amyloid deposits cause AD, the Abeta hypothesis is more inclusive in that it takes into account the possibility that several different Abeta assemblies might contribute to AD pathogenesis and not merely the detectable amyloid deposits within the brain. Significantly, the Abeta hypothesis has provided the rationale for a plethora of therapeutic interventions that target Abeta production, aggregation or clearance. Indeed, AD research is entering an exciting phase in which strategies derived from basic research will be tested in humans. Despite this progress, many aspects of AD pathogenesis, particularly those downstream of Abeta accumulation are not well understood. Herein, we explore several observations that serve to illustrate the more enigmatic aspects of the Abeta hypothesis, and discuss why further basic research may be critical in order to develop therapies designed to halt neurodegeneration and reverse cognitive decline in patients already suffering from AD dementia.
Similar articles
- Alzheimer's disease.
De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. De-Paula VJ, et al. Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Subcell Biochem. 2012. PMID: 23225010 Review. - Untangling amyloid-β, tau, and metals in Alzheimer's disease.
Savelieff MG, Lee S, Liu Y, Lim MH. Savelieff MG, et al. ACS Chem Biol. 2013 May 17;8(5):856-65. doi: 10.1021/cb400080f. Epub 2013 Mar 18. ACS Chem Biol. 2013. PMID: 23506614 Review. - Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.
Barage SH, Sonawane KD. Barage SH, et al. Neuropeptides. 2015 Aug;52:1-18. doi: 10.1016/j.npep.2015.06.008. Epub 2015 Jul 2. Neuropeptides. 2015. PMID: 26149638 Review. - The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease.
Golde TE. Golde TE. Brain Pathol. 2005 Jan;15(1):84-7. doi: 10.1111/j.1750-3639.2005.tb00104.x. Brain Pathol. 2005. PMID: 15779241 Free PMC article. Review. - Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease.
Cho JE, Kim JR. Cho JE, et al. Recent Pat CNS Drug Discov. 2011 Sep 1;6(3):222-33. doi: 10.2174/157488911796958002. Recent Pat CNS Drug Discov. 2011. PMID: 21834780 Review.
Cited by
- Unravelling the Untapped Pharmacological Potential of Plant Molecules as Inhibitors of BACE1: In Silico Explorations for Alzheimer's Disease.
Kalaimathi K, Prabhu S, Ayyanar M, Thiruvengadam M, Shine K, Vijaya Prabhu S, Amalraj S. Kalaimathi K, et al. Appl Biochem Biotechnol. 2024 Aug;196(8):5447-5470. doi: 10.1007/s12010-023-04803-4. Epub 2023 Dec 30. Appl Biochem Biotechnol. 2024. PMID: 38158488 - Soluble brain homogenates from diverse human and mouse sources preferentially seed diffuse Aβ plaque pathology when injected into newborn mouse hosts.
Moore BD, Levites Y, Xu G, Hampton H, Adamo MF, Croft CL, Futch HS, Moran C, Fromholt S, Janus C, Prokop S, Dickson D, Lewis J, Giasson BI, Golde TE, Borchelt DR. Moore BD, et al. Free Neuropathol. 2022 Jan 11;3(9):3-9. doi: 10.17879/freeneuropathology-2022-3766. Epub 2022 Mar 23. Free Neuropathol. 2022. PMID: 35494163 Free PMC article. - Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment.
Hu Y, Kirmess KM, Meyer MR, Rabinovici GD, Gatsonis C, Siegel BA, Whitmer RA, Apgar C, Hanna L, Kanekiyo M, Kaplow J, Koyama A, Verbel D, Holubasch MS, Knapik SS, Connor J, Contois JH, Jackson EN, Harpstrite SE, Bateman RJ, Holtzman DM, Verghese PB, Fogelman I, Braunstein JB, Yarasheski KE, West T. Hu Y, et al. JAMA Netw Open. 2022 Apr 1;5(4):e228392. doi: 10.1001/jamanetworkopen.2022.8392. JAMA Netw Open. 2022. PMID: 35446396 Free PMC article. - Pharmacological intervention in a transgenic mouse model improves Alzheimer's-associated pathological phenotype: Involvement of proteasome activation.
Mladenovic Djordjevic AN, Kapetanou M, Loncarevic-Vasiljkovic N, Todorovic S, Athanasopoulou S, Jovic M, Prvulovic M, Taoufik E, Matsas R, Kanazir S, Gonos ES. Mladenovic Djordjevic AN, et al. Free Radic Biol Med. 2021 Jan;162:88-103. doi: 10.1016/j.freeradbiomed.2020.11.038. Epub 2020 Dec 3. Free Radic Biol Med. 2021. PMID: 33279620 Free PMC article. - Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials.
Petrushina I, Hovakimyan A, Harahap-Carrillo IS, Davtyan H, Antonyan T, Chailyan G, Kazarian K, Antonenko M, Jullienne A, Hamer MM, Obenaus A, King O, Zagorski K, Blurton-Jones M, Cribbs DH, Lander H, Ghochikyan A, Agadjanyan MG. Petrushina I, et al. Neurobiol Dis. 2020 Jun;139:104823. doi: 10.1016/j.nbd.2020.104823. Epub 2020 Feb 28. Neurobiol Dis. 2020. PMID: 32119976 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical